These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1069558)

  • 1. Immunotherapy of osteosarcoma patients with virus-modified tumor cells.
    Green AA; Pratt C; Webster RG; Smith K
    Ann N Y Acad Sci; 1976; 277(00):396-411. PubMed ID: 1069558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific antitumor effects of tumor vaccine produced by autologous dendritic cells transfected with allogeneic osteosarcoma total RNA through electroporation in rats.
    Yu Z; Sun H; Zhang T; Yang T; Long H; Ma B
    Cancer Biol Ther; 2009 May; 8(10):973-80. PubMed ID: 19287216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The therapy of osteogenic sarcoma: current status and thoughts for the future.
    Friedman MA; Carter SK
    J Surg Oncol; 1972; 4(5):482-510. PubMed ID: 4566220
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness evaluation of dendritic cell immunotherapy for osteosarcoma on survival rate and in vitro immune response.
    Fang X; Jiang C; Xia Q
    Genet Mol Res; 2015 Oct; 14(4):11763-70. PubMed ID: 26436501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsumura H
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
    Weibo P; Zhaoming Y
    Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial: New therapies for osteogenic sarcoma.
    Campbell CJ; Cohen J; Enneking WF
    J Bone Joint Surg Am; 1975 Mar; 57(2):143-4. PubMed ID: 1054022
    [No Abstract]   [Full Text] [Related]  

  • 8. Transfer factor therapy in osteogenic sarcoma.
    Levin AS; Byers VS; Fudenberg HH; Wybran J; Hackett AJ; Johnston JO
    Trans Assoc Am Physicians; 1974; 87():153-8. PubMed ID: 4549141
    [No Abstract]   [Full Text] [Related]  

  • 9. Longitudinal studies of cellular immunity of patients with osteogenic sarcoma during chemoimmunotherapy.
    Sears HF; Simon R; Rosenberg SA
    Cancer Treat Rep; 1980; 64(4-5):589-97. PubMed ID: 6933004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma.
    Rainusso N; Brawley VS; Ghazi A; Hicks MJ; Gottschalk S; Rosen JM; Ahmed N
    Cancer Gene Ther; 2012 Mar; 19(3):212-7. PubMed ID: 22173710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new antisarcoma strategy: multisubtype heat shock protein/peptide immunotherapy combined with PD-L1 immunological checkpoint inhibitors.
    Li H; Sui X; Wang Z; Fu H; Wang Z; Yuan M; Liu S; Wang G; Guo Q
    Clin Transl Oncol; 2021 Aug; 23(8):1688-1704. PubMed ID: 33792840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune approaches to treating osteosarcoma.
    Marina N; Gorlick R
    Cancer Biol Ther; 2009 May; 8(10):981-3. PubMed ID: 19395866
    [No Abstract]   [Full Text] [Related]  

  • 13. [Inducing specific antitumor effects on osteosarcoma by fused vaccine of rat dendritic cells].
    Yu Z; Fan QY; Ma BA; Hao XB; Long H
    Ai Zheng; 2005 Mar; 24(3):285-91. PubMed ID: 15757528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line.
    Nabeta Y; Kawaguchi S; Sahara H; Ikeda H; Hirohashi Y; Goroku T; Sato Y; Tsukahara T; Torigoe T; Wada T; Kaya M; Hiraga H; Isu K; Yamawaki S; Ishii S; Yamashita T; Sato N
    J Orthop Sci; 2003; 8(4):554-9. PubMed ID: 12898310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological studies in murine osteosarcoma. Immunogenicity, growth kinetics, and immunotherapy.
    Miller CW; DeBlasi RF; Fisher SJ
    J Bone Joint Surg Am; 1976 Apr; 58(3):312-7. PubMed ID: 1063129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applying Osteosarcoma Immunology to Understand Disease Progression and Assess Immunotherapeutic Response.
    Pratt HG; Justin EM; Lindsey BA
    Adv Exp Med Biol; 2020; 1258():91-109. PubMed ID: 32767236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances on immunotherapy for osteosarcoma.
    Yu S; Yao X
    Mol Cancer; 2024 Sep; 23(1):192. PubMed ID: 39245737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response to sarcomas. A review.
    Weinert CR; McMaster JH; Ferguson RJ
    Clin Orthop Relat Res; 1974; (102):207-16. PubMed ID: 4529323
    [No Abstract]   [Full Text] [Related]  

  • 19. Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency.
    Hanitsch LG; Löbel M; Mieves JF; Bauer S; Babel N; Schweiger B; Wittke K; Grabowski P; Volk HD; Scheibenbogen C
    Vaccine; 2016 May; 34(21):2417-2423. PubMed ID: 27055021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
    Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
    Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.